CN113767106A - 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途 - Google Patents

氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途 Download PDF

Info

Publication number
CN113767106A
CN113767106A CN202080031864.3A CN202080031864A CN113767106A CN 113767106 A CN113767106 A CN 113767106A CN 202080031864 A CN202080031864 A CN 202080031864A CN 113767106 A CN113767106 A CN 113767106A
Authority
CN
China
Prior art keywords
alkyl
group
alkoxy
halo
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080031864.3A
Other languages
English (en)
Other versions
CN113767106B (zh
Inventor
周福生
蔡礼健
蒋涛
赵吉辰
刘颖涛
赵金柱
张磊涛
刘柱博
彭灵
何宛
杨华彬
张涛
丁茜
郑彪
吕强
兰炯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genfleet Therapeutics Shanghai Inc
Zhejiang Genfleet Therapeutics Co Ltd
Original Assignee
Genfleet Therapeutics Shanghai Inc
Zhejiang Genfleet Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfleet Therapeutics Shanghai Inc, Zhejiang Genfleet Therapeutics Co Ltd filed Critical Genfleet Therapeutics Shanghai Inc
Publication of CN113767106A publication Critical patent/CN113767106A/zh
Application granted granted Critical
Publication of CN113767106B publication Critical patent/CN113767106B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

一种对KRAS基因突变具有选择抑制作用的氧杂氮杂喹唑啉‑7(8H)‑酮类化合物及其药学上可接受的盐、立体异构体、溶剂化合物或前药，如式I或式II所示，式中各基团的定义详见说明书。此外，本发明还公开了包含该化合物的药物组合物，及其在制备癌症药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (39)

  1. PCT国内申请，权利要求书已公开。
CN202080031864.3A 2019-04-28 2020-04-28 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途 Active CN113767106B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910349813 2019-04-28
CN2019103498134 2019-04-28
PCT/CN2020/087428 WO2020221239A1 (zh) 2019-04-28 2020-04-28 氧杂氮杂喹唑啉-7(8h)-酮类化合物，其制法与医药上的用途

Publications (2)

Publication Number Publication Date
CN113767106A true CN113767106A (zh) 2021-12-07
CN113767106B CN113767106B (zh) 2024-02-20

Family

ID=73029647

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080031864.3A Active CN113767106B (zh) 2019-04-28 2020-04-28 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途

Country Status (6)

Country Link
US (1) US20220251109A1 (zh)
EP (1) EP3964516A4 (zh)
JP (1) JP7280975B2 (zh)
KR (1) KR20220012255A (zh)
CN (1) CN113767106B (zh)
WO (1) WO2020221239A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112390818A (zh) * 2019-08-12 2021-02-23 劲方医药科技(上海)有限公司 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途
CN113980032A (zh) * 2020-07-27 2022-01-28 江苏恒瑞医药股份有限公司 稠合四环类衍生物、其制备方法及其在医药上的应用
CN114040914A (zh) * 2019-07-01 2022-02-11 江苏恒瑞医药股份有限公司 喹唑啉酮类衍生物、其制备方法及其在医药上的应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
WO2020085493A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 新規なインダゾール化合物又はその塩
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
AU2020325477A1 (en) * 2019-08-02 2022-03-17 Jiangxi Jemincare Group Co., Ltd Tetracyclic compound, preparation method therefor and use thereof
EP4021444A4 (en) 2019-08-29 2023-01-04 Mirati Therapeutics, Inc. G12D KRAS INHIBITORS
CA3152025A1 (en) 2019-09-24 2021-04-01 David BRIERE Combination therapies
JP7340100B2 (ja) 2019-10-28 2023-09-06 メルク・シャープ・アンド・ドーム・エルエルシー Ｋｒａｓ ｇ１２ｃ変異型の小分子阻害薬
CN115135315A (zh) 2019-12-20 2022-09-30 米拉蒂治疗股份有限公司 Sos1抑制剂
WO2022111624A1 (zh) * 2020-11-27 2022-06-02 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
AU2022280025A1 (en) * 2021-05-25 2023-12-07 Erasca, Inc. Sulfur-containing heteroaromatic tricyclic kras inhibitors
AU2022314009A1 (en) * 2021-07-23 2024-01-25 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
TW202322819A (zh) * 2021-10-22 2023-06-16 大陸商江蘇恆瑞醫藥股份有限公司 含氮的四環化合物、其製備方法及其在醫藥上的應用
WO2024002024A1 (zh) * 2022-06-27 2024-01-04 石药集团中奇制药技术（石家庄）有限公司 三环类化合物及其用途
WO2024031088A1 (en) 2022-08-05 2024-02-08 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2024032703A1 (en) * 2022-08-11 2024-02-15 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer
WO2024153119A1 (en) * 2023-01-18 2024-07-25 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017058805A1 (en) * 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2018206539A1 (en) * 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
WO2018217651A1 (en) * 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202012415A (zh) * 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017058805A1 (en) * 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2018206539A1 (en) * 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
WO2018217651A1 (en) * 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114040914A (zh) * 2019-07-01 2022-02-11 江苏恒瑞医药股份有限公司 喹唑啉酮类衍生物、其制备方法及其在医药上的应用
CN112390818A (zh) * 2019-08-12 2021-02-23 劲方医药科技(上海)有限公司 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途
CN112390818B (zh) * 2019-08-12 2023-08-22 劲方医药科技(上海)有限公司 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途
CN113980032A (zh) * 2020-07-27 2022-01-28 江苏恒瑞医药股份有限公司 稠合四环类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
WO2020221239A1 (zh) 2020-11-05
JP2022531196A (ja) 2022-07-06
US20220251109A1 (en) 2022-08-11
CN113767106B (zh) 2024-02-20
JP7280975B2 (ja) 2023-05-24
KR20220012255A (ko) 2022-02-03
EP3964516A4 (en) 2023-01-11
EP3964516A1 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
CN113767106A (zh) 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途
CN113853373B (zh) 取代的杂环并环类化合物，其制法与医药上的用途
CN112390818A (zh) 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途
WO2020177629A1 (zh) 螺环取代的嘧啶并环类化合物，其制法与医药上的用途
CN112110918A (zh) 螺环取代的嘧啶并环类化合物，其制法与医药上的用途
CN115551867A (zh) 稠合三环类化合物、其药物组合物及用途
TWI680970B (zh) 可做為ｓｕｍｏ活化酵素抑制劑之雜芳基化合物
US20220363681A1 (en) Oxo six-membered cyclopyrimidine compound, preparation method and medical use thereof
CN114615981A (zh) Kras g12d抑制剂
EP4332105A1 (en) Pyridino- or pyrimido-cyclic compound, preparation method therefor and medical use thereof
CN113508118A (zh) 用作抗癌剂的稠合三环化合物
TW202140450A (zh) 用於癌症治療的ｋｒａｓ抑制劑
WO2022135470A1 (zh) 作为kras抑制剂的杂环化合物的制备及其应用方法
CN112047937B (zh) 四氢吡啶并[3,4-d]嘧啶-2(1H)-酮类化合物，其制法与医药上的用途
CN115867346A (zh) 激酶抑制剂
WO2022184152A1 (zh) 稠环取代的六元杂环化合物及其制法和用途
CN113387962A (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
CN115667226A (zh) 作为egfr抑制剂的三环化合物
WO2023280254A1 (zh) 一种tead抑制剂
WO2022063101A1 (zh) 芳甲酰取代的三环化合物及其制法和用途
CN115135648A (zh) 二氢萘啶酮类化合物，其制法与医药上的用途
RU2815814C1 (ru) Замещенное гетероциклическое конденсированное циклическое соединение, способ его получения и его фармацевтическое применение
WO2023131122A1 (zh) 稠环取代的六元杂环化合物及其制法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40064286

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant